Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

ACX-362E [Ibezapolstat] for Oral Treatment of Clostridioides Difficile Infection: A Phase 2A Open-Label Segment Followed by a Phase 2B Double-Blind Vancomycin-Controlled Segment

NCT04247542 is registered in ClinicalTrials.gov with Acurx Pharmaceuticals Inc. as lead sponsor.

NCT NCT04247542
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04247542 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
ACX-362E [Ibezapolstat] for Oral Treatment of Clostridioides Difficile Infection: A Phase 2A Open-Label Segment Followed by a Phase 2B Double-Blind Vancomycin-Controlled Segment
Lead sponsor
Acurx Pharmaceuticals Inc.
Phase
Phase 2
Overall status
Completed
Start date
March 6, 2020
Completion date
November 15, 2023
Enrollment
53 (actual)
Sites
29

Conditions

As the registry lists them; a condition with its own page is linked.

clostridium difficile infection